Navigation Links
Study: Ipilimumab Shows Durable Responses But Low Overall Response Rate In Patients With Unresectable Or Metastatic Mucosal Melanoma
Date:5/28/2013

Durham, NC (PRWEB) May 28, 2013

Treatment with ipilimumab can result in durable antitumor effects despite a low overall response rate in patients with advanced mucosal melanoma (MM). Richard D. Carvajal, MD, Medical Oncologist at the Memorial Sloan-Kettering Cancer Center in New York, led the multicenter, retrospective study, recently published in The Oncologist, in collaboration with researchers from the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston.

Melanoma arising from the mucosal surfaces is a rare form of melanoma that differs clinically and biologically from cutaneous melanoma and is associated with a poor prognosis. To date, no prospective trials for patients with MM have been published, and the most effective systemic therapy has not been defined. Ipilimumab is currently a standard of care for patients with unresectable or metastatic melanoma, but its potential role in the treatment of patients with MM is unknown.

In the current study, researchers examined radiographic tumor response at 12 weeks, overall survival, and toxicity in 33 patients who received treatment with single-agent ipilimumab at one of the three participating institutions. All patients had unresectable or metastatic melanoma of primary mucosal origin, and 76% had received prior systemic therapy for metastatic disease. Twenty-five patients (76%) received a median of 4 doses of ipilimumab 3 mg/kg (range, 2 to 8 doses), and 24% received a median of 4 doses of ipilimumab 10 mg/kg (range, 2 to 17 doses). The most common immune-related adverse events were rash in 6 patients, diarrhea in 3 patients, and 1 case each of thyroiditis, hepatitis, and hypophysitis.

Among 30 evaluable patients, radiographic assessment at 12 weeks showed 1 complete response (CR), 1 partial response (PR), and 6 cases of stable disease. The overall response rate was 6.7%. The patient who achieved CR was aged 87 years at the time of i
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. A pan-European study: Signs of motor disorders can appear years before disease manifestation
2. Study: Older Whooping Cough Vaccine More Effective
3. Study: Peer-referral programs can increase HIV-testing in emergency departments
4. Study: Patient openness to research can depend on race and sex of study personnel
5. Study: Brain makes call on which ear is used for cell phone
6. Study: HIV Infection Does Not Adversely Affect Outcomes of Liver Transplantation for Hepatocellular Carcinoma
7. Penn pilot study: Group of Bradford Co, Pa. residents concerned about health effects of hydrofracking
8. Great HealthWorks, Inc., makers of Omega XL, Report New Independent Study: Omega-3 DHA Protects Against Liver Disease
9. New IU study: How often is more important than why when describing breakups
10. Study: Physicians less likely to bond with overweight patients
11. The doctor wont see you now? Study: US facing a neurologist shortage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... ... solutions for drugs, biologics and consumer health products, today welcomed the announcement by ... OPKO’s New Drug Application for a new treatment for chronic kidney disease (CKD) ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today ... management solution, as well as announced the date of its next major release. ... of contract management tasks as well as enhancements to the customer experience. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... of it’s new program “Designing Secure Healthcare Systems” This three-day, highly interactive ... leaders from healthcare organizations with access to the tactics, techniques and practices required ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article ... Stem Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" ... to the report, the new study showed that harvesting stem cell-rich bone marrow from ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... firm, announced today that Joe Williams has joined its growing California employee benefits ... HUB's differentiated service model to his clients. Mr. Williams will be joining the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... too many clinicians still using unproven treatments , , ... and teens, individual and group cognitive behavioral therapy ... and other trauma symptoms, say U.S. researchers who ... subject. , However, despite the proven effectiveness of ...
... a criminal plea and pay $425 million to resolve ... by the Food and Drug,Administration (FDA), the Justice Department ... Cephalon employees and filed under,the qui tam provisions of ... in a scheme to market Gabitril, Actiq and Provigil ...
... Food Prices on the Rise New Tools to Help Make ... finance expert Suze Orman,is the latest celebrity to join the ... their health. With rising food costs, many,families are economizing on ... nutrition. At about 25 cents per 8 ounce glass, on ...
... In a letter to Dr. Mary S. ... ) board,s Governance Committee, the,CtW Investment Group questions ... Walgreens and challenges the arguments put forward by ... of Longs. Citing analysis prepared by expert anti-trust ...
... Pa., Sept. 29 Herley Industries,Inc. (Nasdaq: ... England division in,Woburn, Massachusetts, has a contract totaling ... NY, for the manufacture of,complex switch filter assemblies ... ("ESM") system., The MH-60R Multi-Mission Helicopter (MMH) ...
... LegalView recently informed mesothelioma blog readers of improper removal of asbestos ... risk for developing mesothelioma cancer. The city used an unapproved "wet ... asbestos dust once the water evaporates. , ... Denver, ...
Cached Medicine News:Health News:Cognitive Behavioral Therapy Best for Traumatized Youths 2Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 2Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 3Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 4Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 5Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 2Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 3Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 2Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 3Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 4Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 5Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 6Health News:Herley New England Receives Additional $1.3 Million Contract Award from Lockheed Martin for the Multi-Mission Helicopter 2Health News:LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition 2Health News:LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition 3
(Date:8/3/2015)... ZIONA, Israel , August 3, 2015 ... BVXV) today announced it received the statistical analysis of results ... (M-001), administered in the BVX-005 phase II trial which took ... strains which did not exist at the time of the ... strain that caused the epidemic in the United ...
(Date:8/3/2015)... 3, 2015  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... an exclusive licensing agreement to develop and commercialize multiple ... Limited, a holding company for premier antibody development and ... Under the terms of the agreement, Sorrento ... for the North American, European and Japanese market. Each ...
(Date:7/31/2015)... 31, 2015  Physicians and payers alone do ... market. Patients are better informed and getting increasingly ... therapies. This shift in power is reshaping the ... patient-focused marketing. As part of this ... it,s important to educate, communicate and engage patients ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
... The proprietary Ambient Noise Reduction ... out anaverage of 75% of distracting ... acoustic canceling effect is different from ... out some portions of body sounds ...
... Afinion AS100 Analyzer ... on-the-spot testing, regardless of ... test was launched in ... CRP test in May ...
... Virion\Serions comprehensive line of ELISA Classic serology ... viral, and fungal pathogens with rapid, standardized ... IgA antibodies. All of the ELISA antigens ... in their own laboratories under the control ...
Medicine Products: